MyMitochondria — teal mitochondrion icon and my Mitochondria wordmarkScience & Health Powering Your CellsFind a Clinic
Latest edition · Mitochondrial medicine, translated without the hype
Research snapshot · Nov 15, 2026
Follow us on Google
CBD shrank abnormally swollen mitochondria back toward normal — mitochondrial enlargement in Barth syndrome
Medications Cell study

CBD shrank abnormally swollen mitochondria back toward normal — in Barth syndrome cells

Edited by Samael A. Tejada, Founder & Editor-in-Chief

·
The short answer

Cannabidiol reduced the share of abnormally large mitochondria in cells derived from boys with Barth syndrome from 18.2% to 2%, restoring average mitochondrial size to healthy-control levels (Biochemical and Biophysical Research Communications, November 5, 2026). The internal cristae defect was not fixed, and the work is in cultured cells only — nobody was treated.

Barth syndrome already has one mitochondria-targeted medicine story — the first approved drug for the condition works on cardiolipin. This study asks whether a very different molecule, CBD, can correct a different part of the same cellular picture: mitochondrial size.

What exactly did CBD change?

Examined by transmission electron microscopy, untreated Barth syndrome cells held mitochondria significantly larger than healthy controls'. After CBD treatment, average mitochondrial size fell to levels comparable with healthy cells, and abnormally large mitochondria dropped from 18.2% of the total to 2%. The researchers also found a candidate mechanism: phosphorylation at a specific site on DRP1 — a protein that drives mitochondrial division — ran at nearly three times the normal level in untreated Barth cells, which would inhibit division and let mitochondria balloon; CBD brought that phosphorylation back to near-normal, and produced no comparable changes in healthy cells.

What did CBD not fix?

The cristae. The length of the internal membrane folds where energy production happens was not significantly restored, so part of the structural abnormality remained even as size normalised. The result also sits in a specific and limited system: one cell type (B-lymphoblastoid cells) derived from a small number of young patients, in culture.

How does this fit the team's earlier work?

In March, the same Waterloo group reported that CBD restored cell growth, improved mitochondrial respiration and normalised several cardiolipin measures in Barth syndrome-derived cells. Together the studies describe CBD acting on several of the disorder's cellular abnormalities — membrane composition, respiration, and now size regulation. That is a coherent preclinical picture, and it is still preclinical: cell findings have a long record of not surviving contact with patients, and CBD itself carries drug-interaction and dosing questions that a cell study cannot answer.

Frequently asked questions

What is Barth syndrome?

A rare genetic disorder caused by mutations in TAFAZZIN, which maintains cardiolipin — a lipid essential to mitochondrial structure. It can cause serious heart, muscle and immune complications, mainly in boys.

What is DRP1?

Dynamin-related protein 1, the protein that pinches mitochondria in two when they divide. Chemical modification (phosphorylation) at certain sites can stall that process, letting mitochondria grow abnormally large.

Does this mean CBD treats Barth syndrome?

No. It means CBD normalised mitochondrial size in cultured cells from patients. No animal or human treatment evidence exists.

Where the evidence stands

Join the discussion

To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.

Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.

Follow MyMitochondria on Google

Site imagery: photographs and photographic-style imagery — illustrative only. People pictured are not patients, clinicians, endorsers, or cases described in our articles.